BRISTOL-MYERS' RELOCATING SOME ANTIBIOTIC OPERATIONS TO PUERTO RICO AND ITALY
BRISTOL-MYERS' RELOCATING SOME ANTIBIOTIC OPERATIONS TO PUERTO RICO AND ITALY from its Syracuse, N.Y. facility. The move involves filling and packaging operations and a small portion of the bulk manufacturing operation. The Syracuse facility will be phased out over the next 15-18 months and the operations consolidated into existing plants in Barceloneta, Puerto Rico and Latina, Italy. The move will affect approximately 200 employees, Bristol-Myers said. The company explained that the decision to relocate its antibiotic operations was based on the fact that the design and layout of the Syracuse facilities "makes it increasingly difficult to produce with competitive efficiency." Bristol-Myers stated that it "looked closely at redesigning and rebuilding the structures" to meet the company's needs, "but the cost was prohibitive and excess capacity already exists in" the Barceloneta and Latina plants. No decision has been made as to what will be done with the closed facilities. Bristol-Myers noted that "no regular employee will be displaced before April, 1985." In addition, the company said it has created an employee assistance program "which includes special severance pay based on age and length of service, an early retirement package, continued medical coverage, and assistance in finding new employment." Approximately 1,600 people will remain in Syracuse in the Bristol-Myers Industrial and Bristol Labs Divs.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.